TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05730426

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep dry needling
Description: Method to decrease pain and improve function in musculoskeletal disorders.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy technique
Description: Method to decrease pain and improve function in musculoskeletal disorders.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Neck stability exercise
Description: Method to decrease pain and improve function in musculoskeletal disorders.
Study: NCT05107661

Intervention type: BEHAVIORAL
Intervention: Telephone Prompt
Description: Scripted messaging to remind subjects to complete their colorectal screening (colonoscopy or fecal test)

Intervention type: BEHAVIORAL
Intervention: Telephone Prompt
Description: Scripted messaging to remind subjects to complete their colorectal screening (colonoscopy or fecal test)
Study: NCT05470452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The reading process is assisted by ENDOANGEL
Description: Diagnosis of benign and malignant lesions with the help of ENDOANGEL

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No ENDOANGEL assistance during the reading process
Description: Diagnosis of benign and malignant lesions without the help of ENDOANGEL
Study: NCT05602389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VL-G-A57
Description: Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VL-G-E12
Description: Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
Study: NCT06298669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biventricular Pacing
Description: The CRT device will be reprogrammed to coordinate contractions of the left and right ventricles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biventricular Pacing
Description: The CRT device will be reprogrammed to coordinate contractions of the left and right ventricles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right Ventricular Pacing
Description: The CRT device will be reprogrammed for right ventricular contractions.
Study: NCT05772273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusion
Description: The 4 DLI doses (dose range: ±10%) of sib-matched donor HSCT patients were 1×10\^6/kg, 5×10\^6/kg, 1×10\^7/kg, 5×10\^7/kg; The 4 DLI doses (dose range: ±10%) of haploidentical or unrelated donor HSCT patients were 1×10\^5/kg, 5×10\^5/kg, 1×10\^6/kg, 5×10\^6/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg Q2W for sib-matched donor HSCT patients, 100mg Q2W for haploidentical or unrelated donor HSCT patients.
Study: NCT05586802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: This will be an experimental treatment for 26 weeks in Group 1 Arm A and Arm B as well for Group 2 Arm D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: This will be an experimental treatment for 26 weeks in Group 1 Arm A and Arm B as well for Group 2 Arm D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: This will be an experimental treatment for 26 weeks in Group 1 Arm A and Arm B as well for Group 2 Arm D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: This will be an experimental treatment for 26 weeks in Group 2 Arm E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: This will be an experimental treatment for 26 weeks in addition to anastrozole in Group 1 - Arm B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: This will be an active comparator for 26 weeks in Group 2 - Arm C
Study: NCT05574517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without reverse insertion of a ureteral catheter
Description: Traditional tubeless percutaneous nephrolithotomy usually need retrograde ureteral catheter insertion. Our intervention is that the tubeless percutaneous nephrolithotomy is executed without reverse insertion of a ureteral catheter.
Study: NCT05397691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Family Talk
Description: The Modified Family Talk intervention consists of six modules, each lasting approximately 60 minutes. Family Talk is intended to be delivered over a period of 12 weeks, with meetings occurring every 1-2 weeks.
Study: NCT06377423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct technique
Description: The composite was placed directly using free-hand technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect technique
Description: The ceramic was placed using indirect method via laboratory casts
Study: NCT05397691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control-like parameter estimation
Description: Parameter estimation is designed to emulate best practices around comprehensive, high quality, patient-centered care for adults and youth. Participants will have access to collaborative adult Office Based Addiction Treatment (OBAT) clinical services, multidisciplinary adolescent primary care clinics with co-located adolescent substance use specialists, high quality social work services, integrated behavioral health, and access to patient navigators for assistance connecting to community resources.
Study: NCT04831073

Intervention type: PROCEDURE
Intervention: Surgery on the ascending aorta with or without repair of the aortic root and/or aortic arch
Description: Surgical repair of the ascending aorta with or without surgical repair of the aortic root and/or aortic arch
Study: NCT05145140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standardized Western Medicine Treatment
Description: Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standardized Western Medicine Treatment
Description: Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standardized Western Medicine Treatment
Description: Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Western Medicine Treatment
Description: Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
Study: NCT05519865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: 30mg orally BIW
Study: NCT05145140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangningtongluo tablet and cream
Description: Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.There are two dosage forms: tablet and cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangningtongluo tablet
Description: Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangningtongluo cream
Description: Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use cream.
Study: NCT04706559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic sachet containing mixture of four strains i.e.Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii
Description: Interventional group: Children with AD meeting eligibility criteria receiving probiotics and conventional treatment (topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients).
Study: NCT05519865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) Q3W
Study: NCT04706559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients as per atopic dermatitis treatment guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients as per atopic dermatitis treatment guidelines.
Study: NCT06609135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentec LuMon Device (EIT system)
Description: Sentec EIT belts will be placed on infants up to once daily from consent through NICU discharge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentec Digital Monitoring System (transcutaneous CO2 monitor)
Description: Sentec transcutaneous CO2 monitors will be placed on infants concurrently with EIT belts.
Study: NCT06611215

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Prebiotic 1 - Stick pack of combination 1 of two polysaccharides mixed with a glass of water each morning

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 - stick pack of maltodextrin 1 mixed with a glass of water each morning

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Prebiotic 2 - Stick pack of combination 2 of two polysaccharides mixed with a glass of water each morning

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 - stick pack of maltodextrin 2 mixed with a glass of water each morning
Study: NCT06610773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUC-MSCs
Description: 1×10\^6/Kg hUC-MSCs (suspended in 100 mL normal saline containing 5% albumin) are infused intravenously to patients at a controlled rate of 60-80 drops/min.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline+albumin
Description: Normal saline containing 5% albumin had a similar suspension and appearance package to hUC-MSCs, but no MSCs
Study: NCT06610513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided imagery
Description: First meeting: The women will be introduced to the clinic, the purpose of the study will be explained, and a written consent form will be filled out. A Personal Information Form and the Pregnancy Stress Assessment Scale (GSDS-36) and the Richard-Campbell Sleep Scale will be filled out. After the questionnaires are filled out, the vital signs of the pregnant woman will be measured and then a 15-minute guided imagery video will be shown. The vital signs of the patient will be measured again 10 minutes after the guided imagery video is watched.
Study: NCT05265117

Intervention type: PROCEDURE
Intervention: HIPEC
Description: HIPEC is given after primary or interval debulking surgery.
Study: NCT04801212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises with teeth clenching
Description: The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core stability exercises
Description: The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises
Description: The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
Study: NCT06473584

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diabetes detection
Description: Fasting glycemia on blood sample
Study: NCT05164978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEP combine with PD-1 antibody
Description: Doxorubicin hydrochloride liposome injection 25 mg/m2 day 1 Etoposide 100 mg/m2 day1 Methylprednisolone 1.5 mg/kg days 1 to day 3, 0.25mg/kg days 4 to 14 Sintilimab Injection 200mg d4
Study: NCT04808583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLH with uterine artery ligation at its origin at the beginning of the operation
Description: After insertion of the ports and surveying the abdomen as in the conventional method a window will be created in the broad ligament to enter the retroperitoneal space with exposure of the iliac vessel and identification of the internal iliac artery and its anterior branch which give rise to the uterine artery. Blunt dissection continues with identification of the paravesical and the pararectal spaces. The ureter is identified medially and the uterine artery laterally and dissection of the ureter away from the uterine artery will be done, followed by sealing the uterine artery 2 mm from its origin from the anterior branch of internal iliac artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional TLH with uterine artery ligation after the cornual pedicles
Description: Coagulation and section of round ligaments will be performed about 2 to 3 cm from the pelvic wall using blunt tip laparoscopic sealer LigaSure COVIDIEN (5mm-37cm) with average of sealing cycle of 2 to 4 seconds and 40 watts , followed by opening the anterior leaflet of the broad ligament to the vesico-uterine peritoneal reflection, coagulation and section of the infundibulo-pelvic ligament (total hysterectomy with bilateral adnexectomy) or of the uteroovarian ligament and the fallopian tubes (total hysterectomy). Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014).~Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
Study: NCT06492629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Intravenous infusion, 240mg, administered once every 3 weeks, until the subject has been treated for 2 years, disease progression occurs, intolerable toxic reactions are experienced, or treatment is discontinued for other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: Take 30 mg (6 tablets) each time, and take the medication twice a week, with at least 3 days between doses (such as on Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), to be taken 30 minutes after meals.
Study: NCT06211023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1921
Description: SHR-1921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin AUC 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin AUC 5

Intervention type: DRUG
Group type: OTHER
Intervention: platinum-based doublet chemotherapy
Description: platinum-based doublet chemotherapy
Study: NCT04939467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone 267 mg Oral Tablet
Description: Fixed sequence use of active product, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg Oral Capsule
Description: Fixed sequence use of active product, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-0409 750 mg Oral Tablet
Description: Fixed sequence use of active product, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-0409 750 mg Oral Tablet
Description: Fixed sequence use of active product, QD
Study: NCT05863442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soliris 300 MG in 30 ML Injection
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUR03 300 MG in 30 ML Injection
Description: Investigational medicinal Product, eculizumab - Turgut
Study: NCT05105256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Patient will have 1 infiltration of 3mL to 5 mL of PRP on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with PRP will be performed at inclusion.
Study: NCT06481787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonorasan Fumarate
Description: Vonorasan fumarate is taken 30min before breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonorasan Fumarate
Description: Vonorasan fumarate is taken 30min before breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuojin Pills
Description: Zuojin Pills should be taken 30min after breakfast and dinner.
Study: NCT05426746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-100
Description: intravenous infusion of drug substance diluted in 0.9% normal sterile saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: intravenous infusion of placebo (0.9% normal sterile saline)
Study: NCT04526002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS)
Description: TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses, as done routinely by others. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 70-120%\* resting motor threshold (RMT) (The ideal %RMT will be determined first in a pilot study). In part two, stimulation intensity for patients will be 120% RMT (titration to full therapeutic dose over the first three days), as approved by the FDA in the U.S. (Blumbeger et al. 2018). The stimulation site will be the same as in the concurrent TBS/fNIRS stimulation (see above).
Study: NCT04500574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost eluting contact lens
Description: The latanoprost-contact lens will be worn in one eye for one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Latanoprost
Description: A commercial contact lens with no drug will be worn in one eye for one week.
Study: NCT04785417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: touch screen tablet
Description: traditional occupational therapy in addition to games on tablet
Study: NCT05707221

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cleaning removable acrylic appliance with denture brush and chlorhexidine toothpaste
Description: mechanical cleaning of removable appliance by the patient for 7 days before bedtime for one minute

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cleaning removable acrylic appliance with cleansing tablet
Description: chemical cleaning by patient for 7 days with cleansing tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combination of mechanical and chemical cleaning
Description: cleaning the appliance with denture brush and CHX toothpaste followed by the cleansing tablet
Study: NCT06332222

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart Cherry
Description: 7 day supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 day supplementation
Study: NCT06101238

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation with low dose elemental iron
Description: 65mg daily
Study: NCT05609669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CADENCE program
Description: The CADENCE program will consist of an integrated care pathway between the OBOT clinic, obstetric clinic, pediatric clinic, and behavioral health with multiple entry points, including emergency rooms, existing mobile harm reduction clinics, obstetric clinics, and delivery facilities. We also seek to provide wrap-around care for these families with peer support, care navigation, and robust community support, using existing Hillsborough County resources such as doula programs, Healthy Start, and other home visiting programs.
Study: NCT05869799

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vigiis 101 Lactobacillus Capsules
Description: Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.0 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Maltodextrin was used as a placebo
Study: NCT05500586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon response study
Description: Please see information in group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon response study
Description: Please see information in group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon response study
Description: Please see information in group descriptions